Sign inJoin
Company / Finance

Agilent Technologies, Inc.

A · NYSE

Agilent's CrossLab segment is becoming the quiet efficiency layer for regulated pharma labs: services, consumables, software, automation, and asset monitoring. The proof gate is whether CrossLab can keep growing while margin stays strong.

FollowAdd to WatchlistAsk Question
NYSEAAgilentCrossLabLife Sciences ToolsPharmaceutical Labs
Latest ReportJun 5, 2026Agilent CrossLab Is Secretly Solving The Efficiency Crisis Facing Major Pharmaceutical LabsView report ->Total Reports2Published reportsView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters2 of 2 reports match
Clear filters
Selected tags
AgilentNYSE
Clear tags
MatchAny tagAll tags
Latest Thesis

Agilent CrossLab Is Secretly Solving The Efficiency Crisis Facing Major Pharmaceutical Labs

Agilent's CrossLab segment is becoming the quiet efficiency layer for regulated pharma labs: services, consumables, software, automation, and asset monitoring. The proof gate is whether CrossLab can keep growing while margin stays strong.

Jun 5, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Agilent Technologies, Inc.CrossLab Is Secretly Solving The Efficiency Crisis Facing Major Jun 5, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 2 reports ->
ReportTypeUpdatedReadActions
Agilent CrossLab Is Secretly Solving The Efficiency Crisis Facing Major Pharmaceutical LabsAgilent's CrossLab segment is becoming the quiet efficiency layer for regulated pharma labs: services, consumables, software, automation, and asset monitoring. The proof gate is whether CrossLab can keep growing while margin stays strong.NYSEJun 5, 2026Research reportReadSlides
Agilent Technologies (A): the lab-workflow compounder still waiting for the cycle to turnAgilent's CrossLab mix and cash generation point to a durable lab-workflow franchise, but the open question is whether service and consumables strength can outrun instrument-cycle volatility.NYSEMay 13, 2026Research reportReadSlides